Isocitrate dehydrogenase 1 (IDH 1) and O6-methylguanine-DNA methyltransferase (MGMT) were first introduced to the classification and evaluation of prognosis in patients with GBM based on the 2016 revised World Health Organization (WHO) classification of CNS tumors, which deepened our understanding of genome biology in glioma. This evidence concerns the gene MGMT and central nervous system neoplasm.